-
Rodman & Renshaw Reiterate Market Rating And Price Target On Idera Pharmaceuticals
Friday, July 22, 2011 - 11:35am | 40According to Rodman & Renshaw, Idera Pharmaceuticals (NASDAQ: IDRA), PT and market rating are reiterated. Rodman & Renshaw are maintaining their Price Target of $4 and their rating of Outperform. Idera Pharmaceuticals closed yesterday at $1.80.
-
Human Genome Sciences Hits New 52-Week Lows
Friday, July 22, 2011 - 11:01am | 77Many traders and investors see the 52-week high or low as an important indicator. Stocks that have a long-term trend in a certain direction are likely to continue, as that trend is the path of least resistance. In this case, shares of Human Genome Sciences (NASDAQ: HGSI) are hitting new 52-week...
-
Cepheid up Nearly 22% on Better Than Expected Earnings
Friday, July 22, 2011 - 10:57am | 50Cepheid (NASDAQ: CPHD) is up nearly 22% on the better than expected earnings that were announced yesterday after the close. The company reported Q2 EPS of $0.03 vs. $(0.02) Est and revenues $67.0M vs. $60.96M Est. Cepheid is currently trading at $38.48, a gain of $6.85 or 21.66%.
-
NeurogesX, Inc. Announces $20 Million Private Placement
Friday, July 22, 2011 - 10:24am | 182NeurogesX, Inc. (Nasdaq: NGSX) today announced that on July 21, 2011 it entered into a securities purchase agreement in connection with a private placement to a group of institutional accredited investors and, subject to standard closing conditions, is expected to receive approximately $20 million...
-
UPDATE: Morgan Stanley Raising Price Target On Pharmasset
Friday, July 22, 2011 - 8:31am | 124Morgan Stanley is out with a research report on Pharmasset, Inc. (NASDAQ: VRUS) and is raising its price target to $206 from $175, and it has an Overweight rating on shares. In a note to clients, Morgan Stanley writes, "PSI-7977, Pharmasset's key value driver, has demonstrated solid efficacy (...
-
UPDATE: Morgan Stanley Raising Price Target On Alexion Pharmaceuticals
Friday, July 22, 2011 - 8:23am | 142Morgan Stanley is out with a research report on Alexion Pharmaceuticals (NASDAQ: ALXN) and is raising its price target to $61 from $56 after it reported earnings. It has an Overweight rating on shares. In a note to clients, Morgan Stanley writes, "Alexion reported a strong 2Q11 with Soliris sales...
-
Pre-Market Winners
Friday, July 22, 2011 - 8:15am | 105athenahealth (NASDAQ: ATHN) is trading up over 11% after reporting Q2 earnings. Cepheid (NASDAQ: CPHD) is trading up over 10% after reporting earnings. Skyworks Solutions (NASDAQ: SWKS) is trading up near 9% after reporting earnings. Advanced Micro Devices (NYSE: AMD) is trading up over 8% after...
-
UPDATE: Piper Jaffray Lowering Price Target On Human Genome Sciences
Friday, July 22, 2011 - 8:01am | 190Piper Jaffray is out with a research report on Human Genome Sciences (NASDAQ: HGSI) and it is lowering its price target to $31 from $36, but is keeping its Overweight rating. In a note to clients, Piper Jaffray writes, "HGS reported 2Q11 Benlysta sales of $7.8mn, in line with Street estimates of $...
-
UPDATE: Piper Jaffray Raises PT on Cepheid to $39
Friday, July 22, 2011 - 7:57am | 96Piper Jaffray is out with its report today on Cepheid (NASDAQ: CPHD), raising its PT from $38 to $39. In a note to clients, Piper Jaffray writes, "Management increased F2011 guidance to revenue of $265M-$270M (was $245M-$255M) and EPS of $0.08-$0.11 (was ($0.01)-$0.04), which we view as achievable...
-
Piper Jaffray Raises PT On Cepheid To $39
Friday, July 22, 2011 - 6:38am | 26Piper Jaffray has raised the price target on Cepheid (NASDAQ: CPHD) from $38 to $39 and maintains its Overweight rating.
-
Piper Jaffray Lowers PT On Human Genome Sciences To $31
Friday, July 22, 2011 - 6:08am | 28Piper Jaffray has lowered the price target on Human Genome Sciences (NASDAQ: HGSI) from $36 to $31 and maintains its Overweight rating.
-
ISI Provides Color on Human Genome Sciences
Friday, July 22, 2011 - 3:50am | 130ISI provided color on Human Genome Sciences (NASDAQ: HGSI). In a research report published today, ISI stressed some new fey facts about the company. In the report, ISI states, “1. Net pricing of $21k ($32k list price) in Germany (will launch later this week) [we think this price is generally in-...
-
Stock Watch List For Friday, July 22
Thursday, July 21, 2011 - 5:47pm | 1435( click to enlarge ) Pharmacyclics, Inc. (NASDAQ:PCYC) has been hitting higher highs and higher lows amongst strong RSI price points. In fact, the RSI is showing multiple points of overbought periods. The stock has been on a strong bull market rally as %K line has been on top of %D line with...
-
After Hours Earnings Movers
Thursday, July 21, 2011 - 4:53pm | 113A number of companies reported earnings on Thursday after the closing bell. Here is a look at the biggest movers. Cepheid (NASDAQ: CPHD) +9.07% to $34.50 Athenahealth (NASDAQ: ATHN) +9.10% to $53.00 Ruby Tuesday (NYSE: RT) -8.60% to $10.10 Acme Packet (NASDAQ: APKT) -8.09% to $55.25 C.R. Bard...
-
15 Lottery Specials Under $10
Thursday, July 21, 2011 - 3:37pm | 418Unlike any of my other screens, this stock screen focuses on stocks trading under $10/share, and have a market cap of around $1 billion or less. As for the variables that I used in the screen, I focused on fundamentals, particularly companies that have a healthy balance sheet with little debt to...